Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin‐3 and <i>BM‐40/SPARC</i> genes

Porte, Henri; Chastre, Eric; Prévôt, Sophie; Nordlinger, Bernard; Empereur, Sylvie; Basset, Paul; Chambon, Pierre; Gespach, Christian

doi:10.1002/ijc.2910640114

Cited by 174 publications

(145 citation statements)

References 21 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…17 SPARC overexpression has previously been associated with human tumors. 20 Porte et al 21 identified an association of SPARC with colorectal carcinoma, where neoplastic progression was associated with overexpression of the stromelysin-3 and SPARC genes. Massi et al 22 demonstrated in 188 patients with thin (Ͻ0.75 mm) melanoma that SPARC positivity on IHC staining correlated with significantly poorer survival.…”

Section: Discussionmentioning

confidence: 99%

Novel markers for poor prognosis in head and neck cancer

Chin

Boyle

Williams

et al. 2004

Intl Journal of Cancer

147

111

View full text Add to dashboard Cite

Head and neck cancer (HNSCC) is one of the most distressing human cancers, causing pain and affecting the basic survival functions of breathing and swallowing. Mortality rates have not changed despite recent advances in radiotherapy and surgical treatment. We have compared the expression of over 13,000 unique genes in 7 cases of matched HNSCC and normal oral mucosa. Of the 1,260 genes that showed statistically significant differences in expression between normal and tumor tissue at the mRNA level, the three top ranking of the top 5% were selected for further analysis by immunohistochemistry on paraffin sections, along with the tumor suppressor genes p16 and p53, in a total of 62 patients including 55 for whom >4-year clinical data was available. Using univariate and multivariate survival analysis, we identified SPARC/osteonectin as a powerful independent prognostic marker for short disease-free interval (DFI) (p < 0.002) and poor overall survival (OS) (p ‫؍‬ 0.018) of HNSCC patients. In combination with other ECM proteins found in our analysis, PAI-1 and uPA, the association with DFI and OS became even more significant (p < 0.001). Our study represents the first instance of SPARC as an independent prognostic marker in HNSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel markers for poor prognosis in head and neck cancer

Chin

Boyle

Williams

et al. 2004

Intl Journal of Cancer

147

111

View full text Add to dashboard Cite

show abstract

“…Our findings complement the results of previous studies that reported alterations in SPARC expression in various human cancers. The overexpression of SPARC has been detected in melanoma (Ledda et al, 1997a), colorectal cancer (Porte et al, 1995), breast cancer (Bellahcene and Castronovo, 1995), hepatocellular carcinoma (Le Bail et al, 1999), invasive meningiomas , and prostate cancer (Thomas et al, 2000). Moreover, it has been reported that SPARC promotes cell migration and invasion in prostate cancer (Jacob et al, 1999) and glioblastoma (Golembieski et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

“…In the adult, it becomes more restricted, but can be activated in pathologic situations like wound healing (Reed et al, 1993). However, recent evidence suggests that alterations in SPARC expression are common in various human malignancies, including melanoma (Ledda et al, 1997b), glioma (Schultz et al, 2002), invasive meningioma , hepatocellular carcinoma (Le Bail et al, 1999), colon (Porte et al, 1995), breast (Gilles et al, 1998), and prostate (Thomas et al, 2000) cancers. To date, however, there are no detailed studies on SPARC expression in BE and Barrett's-associated adenocarcinoma (EA) of the oesophagus.…”

mentioning

confidence: 99%

Differential SPARC mRNA expression in Barrett's oesophagus

et al. 2003

View full text Add to dashboard Cite

Barrett's oesophagus (BE) is the precursor lesion to adenocarcinoma of the oesophagus. Understanding of the molecular alterations in this multistage process may contribute to improved diagnosis and treatment. Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that modulates cell adhesion and growth. Alterations in SPARC expression have been observed in a variety of solid tumours. The aim of this study was to assess the prevalence and timing of SPARC mRNA expression in Barrett's multistage disease and to investigate the impact of SPARC alterations on the development and progression of this disease. SPARC mRNA expression was measured using a quantitative real-time RT -PCR method in 108 specimens from 19 patients with BE without carcinoma, 20 patients with Barrett's-associated adenocarcinoma (EA), and a control group (CG) of 10 patients without evidence of gastro-oesophageal reflux disease. The median SPARC mRNA expression was significantly upregulated in BE tissues compared to paired normal oesophagus (NE) tissues for the BE group (P ¼ 0.004) and for the EA group (Po0.001). The SPARC mRNA expression was significantly higher in adenocarcinoma of the oesophagus compared to matching NE tissue and compared to Barrett's tissues in the EA group (Po0.001). Furthermore, SPARC expression values were significantly different between metaplastic and dysplastic Barrett's tissues (P ¼ 0.014). In histologically normal squamous oesophagus tissues obtained from carcinoma patients (EA group), the SPARC mRNA expression was significantly higher compared to NE mucosa from the BE group and the CG group (P ¼ 0.03). These findings suggest that the upregulation of SPARC mRNA expression is an early event in the development and progression of BE and EA, and that high SPARC expression may be a clinically useful biomarker for the detection of occult adenocarcinoma, and that a widespread 'field effect' is present in the NE of patients with oesophageal adenocarcinoma.

show abstract

mentioning

confidence: 99%

“…In a study evaluating stromelysins 1 and 2 and matrilysin (PUMP-1) expression in colorectal cancer, the mRNA of the latter enzyme was expressed in 75% of colon carcinomas, whereas the mRNA of the former was not detected (McDonnell et al, 1991). In a recent study, stromelysin 3 mRNA was overexpressed in primary colorectal adenocarcinomas and liver metastases and expression was shown in stromal fibroblasts adjacent to the neoplastic lesions (Porte et al, 1995).A study examining collective expression of gelatinases and matrilysin suggested that the latter may participate early in tumour progression, whereas the former enzymes, in conjunction with matrilysin and other members of the MMP family, may mediate events occurring later in the progressive cascade (Newell et al, 1994).The synthetic metalloproteinase inhibitor, batimastat, has broad spectrum and potent activity against many members of the MMP family (Brown, 1993) and has been shown to inhibit the metastatic spread of the B16 murine melanoma (Chirivi et al, 1994) and the lung and liver colonisation of the human colorectal tumours, AP5LV and C1 70HM2 respectively (Watson et al, 1995). In addition, the agent has been shown to inhibit tumour growth in an ovarian ascites model (Davies et al, 1993).…”

mentioning

confidence: 99%

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model

Watson

Morris²,

Parsons³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21 % of control in mice treated from day 0 (P <0.002) but not day 10. Formation of solid peritoneal deposits was significantly reduced to 77% of vehicle control when batimastat was administered from day 0 (P<0.01) and 69% of control when administered from day 10 (P<0.05). Thus, batimastat has the ability to reduce the volume of ascites forming in SCID mice injected intraperitoneally with the human colorectal cell line, C170HM2, when administered from day 0 but not from day 10. Solid peritoneal tumour deposits were significantly reduced in both treatment groups, highlighting the therapeutic potential of batimastat in this clinical condition.Keywords: metalloproteinase; colorectal cancer; batimastat A large body of evidence now suggests that matrix metalloproteinases (MMPs) play a role in the metastasis of tumour cells (Brown, 1993). Secretion of these enzymes by both normal and malignant cells is in the form of a latent precursor, which is activated by removal of an amino terminal domain (Stetler-Stevenson et al., 1989). These enzymes are implicated in the breakdown of extracellular matrix and vascularisation, which are both critical for successful metastasis, and recent clinical studies have shown MMP to play a role in the spread of human tumour cells Davies et al., 1993).The role of individual enzymes from the MMP family, in both the growth and metastatic spread of colorectal tumours, has been investigated. Activity of type I fibrillar collagenase, a member of the MMP family, has been shown to correlate with histological grade (van der Strappen, 1990). The 72 kDa gelatinase, which breaks down type IV collagenase of basement membrane, correlates with tumour progression, and mRNA studies have revealed the presence of this enzyme in the tissue stroma adjacent to the invasive edge of the cancer (D'Errico et al., 1991; Poulson et al., 1992). The 92 kDa form of gelatinase has been demonstrated by immunocytochemistry to be widespread in colorectal carcinoma, especially in tumours of advanced stage (Jeziorska et al., 1994). In the same study, expression of the enzyme at specific sites in the tumour has been shown to be inversely related to the localisation of type IV collagen. Furthermore, the 92 kDa gelatinase is elevated in the plasma of colon cancer patients (Zucker et al., 1993). In a study evaluating stromelysins 1 and 2 and matrilysin (PUMP-1) expression in colorectal cancer, the mRNA of the latter enzyme was expressed in 75% of colon carcinomas, whereas the mRNA of the former was not detected (McDonnell et al., 1991). In a recent study, stromelysin 3 mRNA was overexpressed in primary col...

show abstract

Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin‐3 and BM‐40/SPARC genes

Cited by 174 publications

References 21 publications

Novel markers for poor prognosis in head and neck cancer

Novel markers for poor prognosis in head and neck cancer

Differential SPARC mRNA expression in Barrett's oesophagus

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model

Contact Info

Product

Resources

About